Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction Longevity Health Holdings (NASDAQ:XAGE) has announced a definitive merger agreement with THPlasma in an all-stock transaction valued at $59 million plus $20 million in earnouts. The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare.THPlasma, a profitable plasma collection company, is expanding from 2 centers in FY24 to 5 centers in FY25, with guaranteed sales agreements worth $100 million annually. The company projects FY2025 revenue of $10 million and expects significant growth to $32 million in FY2026.The combined company will continue trading as XAGE, with THPlasma's George Chi becoming Co-Chairman and CEO. Simultaneously, Longevity announced the termination of its planned 20/20 BioLabs transaction. The merger is expected to close in Q4 2025.

#XAGE #XAGEW Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

www.stocktitan.net/news/XAGE/longevity-heal...

Longevity Health Secures $1.96M Through ATM Sale, Strengthens Position for 20/20 Merger Deal Fresh capital extends biotech firm's runway into Q1 2026 while advancing merger plans. Discover how this ATM sale strengthens their longevity market position. Get details.

#XAGE #XAGEW Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale

www.stocktitan.net/news/XAGE/longevity-heal...

Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs Longevity Health Holdings (NASDAQ: XAGE) has secured continued Nasdaq listing following a favorable decision from the Nasdaq Hearings Panel. The decision allows XAGE to maintain its listing subject to meeting initial listing requirements post-merger with 20/20 BioLabs by September 2, 2025. As part of its strategic compliance plan, XAGE has: 1) Filed an S-4 registration statement for the proposed merger on May 8, 2025, 2) Implemented a 1-for-30 reverse stock split on May 12, 2025. The Panel's decision was based on review of both companies' financial statements and pro forma projections. The company focuses on longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition products.

#XAGE #XAGEW Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs

www.stocktitan.net/news/XAGE/longevity-heal...

Longevity Health Holdings Announces Business Updates Longevity Health Holdings (NASDAQ: XAGE) announced several key business updates. The company has entered into a merger agreement with 20/20 BioLabs on April 11, 2025, with an S-4 prospectus filed on May 8. Q1 unaudited sales showed growth for both companies: XAGE reported $663,000 (+8% YoY) while 20/20 achieved $562,000 (+15% YoY).The company completed a 1-for-30 reverse stock split on May 12, 2025. Both companies plan Q2 product launches: XAGE will introduce a medicated cleanser for medical professionals, while 20/20 will launch a blood inflammatory biomarker test. Additionally, 20/20 initiated a pilot program with Giant Food for their OneTest™ multi-cancer test at 9 stores in Maryland and Virginia. XAGE is exploring additional financing options for Q2 2025.

#XAGE #XAGEW Longevity Health Holdings Announces Business Updates

www.stocktitan.net/news/XAGE/longevity-heal...

Longevity Health Holdings, Inc. Announces Reverse Stock Split Longevity Health Holdings (NASDAQ: XAGE) has announced a 1-for-30 reverse stock split effective May 12, 2025. The split will reduce outstanding shares from approximately 30.1 million to 1 million. Trading on the split-adjusted basis will begin on the Nasdaq Capital Market on May 14, 2025, under the same ticker symbol "XAGE".The reverse split was approved by stockholders on March 24, 2025. Fractional shares will be rounded up to the nearest whole share. No stockholder action is required for those holding shares electronically or in street name. Proportional adjustments will be made to outstanding stock options, warrants, and shares under the 2023 Equity Incentive Plan.

#XAGE #XAGEW Longevity Health Holdings, Inc. Announces Reverse Stock Split

www.stocktitan.net/news/XAGE/longevity-heal...

Strategic $99M Merger: Longevity Health Doubles Revenue With Cancer Detection Pioneer 20/20 BioLabs Strategic merger brings innovative OneTest cancer detection technology and doubles revenue to $8M. Cost synergies exceed $1M. Full analysis of growth potential inside.

#XAGE #XAGEW Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs

www.stocktitan.net/news/XAGE/longevity-heal...